Refine
Has Fulltext
- yes (234)
Is part of the Bibliography
- yes (234)
Year of publication
Document Type
- Journal article (234) (remove)
Language
- English (234) (remove)
Keywords
- depression (19)
- anxiety (13)
- ADHD (12)
- schizophrenia (12)
- Medizin (9)
- DNA methylation (8)
- fMRI (7)
- genetics (7)
- Schizophrenie (6)
- bipolar disorder (6)
- hippocampus (6)
- mice (6)
- COVID-19 (5)
- antidepressant (5)
- epigenetics (5)
- fear conditioning (5)
- neuroprotection (5)
- Alzheimer’s disease (4)
- NPY (4)
- Quantitative anatomy (4)
- behavior (4)
- brain (4)
- dentate gyrus (4)
- fNIRS (4)
- gene expression (4)
- genome-wide association (4)
- major depression (4)
- mental disorders (4)
- mouse model (4)
- near-infrared spectroscopy (4)
- oxidative stress (4)
- panic disorder (4)
- prefrontal cortex (4)
- pregnancy (4)
- psychiatry (4)
- working memory (4)
- 5-HT1A (3)
- 5-HT2C (3)
- Alzheimers disease (3)
- BDNF (3)
- Bipolar disorder (3)
- Cerebellar cortex (3)
- Depression (3)
- EEG (3)
- MDD (3)
- Parkinson’s disease (3)
- age (3)
- amygdala (3)
- antidepressants (3)
- association (3)
- children (3)
- dopamine (3)
- emotion (3)
- emotional regulation (3)
- glucocorticoid receptor (3)
- glucose transporter (3)
- humans (3)
- major depressive disorder (3)
- mental health (3)
- neurodegeneration (3)
- neuroimaging (3)
- neuroinflammation (3)
- neuropathology (3)
- polygenic risk score (3)
- psychiatric disorders (3)
- serotonin (3)
- stress (3)
- substantia nigra (3)
- 5-HT transporter (2)
- 5-HT1A receptor (2)
- 5-HTTLPR (2)
- Albino rats (2)
- Alzheimer's disease (2)
- Big Five (2)
- CSF (2)
- Cerebellum (2)
- Coexpression (2)
- Cytokines (2)
- DNA (2)
- Emotional processing (2)
- FAAH (2)
- FKBP5 (2)
- FMRI (2)
- Fibromyalgia syndrome (2)
- HPA axis (2)
- IAPS (2)
- Lipofuscin (2)
- MEG (2)
- Mice (2)
- OCD (2)
- P300 (2)
- PARK2 (2)
- Parkinson's disease (2)
- Psychiatric disorders (2)
- Psychiatrie (2)
- Purkinje cells (2)
- Stereology (2)
- activation (2)
- active zone (2)
- adversity (2)
- aggression (2)
- aging (2)
- alliance (2)
- alpha-synuclein (2)
- animal behavior (2)
- anterior cingulate cortex (2)
- anxiety disorders (2)
- biomarker (2)
- biomarkers (2)
- cerebellum (2)
- chronic heart failure (2)
- cognitive impairment (2)
- coping (2)
- cortical activation (2)
- dementia (2)
- disease progression (2)
- disorder (2)
- dorsolateral prefrontal cortex (2)
- early recognition (2)
- efficacy (2)
- electroencephalography (2)
- endocannabinoid (2)
- expression (2)
- extinction (2)
- fear (2)
- fear generalization (2)
- fear-potentiated startle (2)
- fibromyalgia (2)
- frontotemporal dementia (2)
- functional magnetic resonance imaging (2)
- gene (2)
- hiPSC (2)
- human behaviour (2)
- illness (2)
- immediate early genes (2)
- inflammation (2)
- insulin receptor (2)
- iron (2)
- knockout (2)
- knockout mice (2)
- lactation (2)
- learning (2)
- life events (2)
- long-term potentiation (2)
- longitudinal studies (2)
- mutation (2)
- myelination (2)
- myocardial infarction (2)
- negative affect (2)
- neurodevelopment (2)
- neuromelanin (2)
- neuropsychiatric disorders (2)
- neuropsychology (2)
- obesity (2)
- oligodendrocyte (2)
- pain (2)
- parietal hypoactivation (2)
- peripartum (2)
- physiology (2)
- plasticity (2)
- prediction (2)
- proteomics (2)
- quality of life (2)
- rat (2)
- reaction time (2)
- regulatory T cells (2)
- reliability (2)
- response inhibition (2)
- sensitivity (2)
- serotonin transporter (2)
- serotonin transporter gene (2)
- social decision-making (2)
- startle reflex (2)
- substantia nigra pars compacta (2)
- suicide prevention (2)
- systematic review (2)
- temporoparietal junction (2)
- transcranial direct current stimulation (2)
- triple in situ hybridization (2)
- tryptophan (2)
- 123I-mIBG (1)
- 1p13.3 (1)
- 1q21 (1)
- 5-HT (1)
- 5-HTT knockout mice (1)
- 5HTTLPR (1)
- 7q11.2 (1)
- Abelson helper integration-1 (AHI1) (1)
- Activation (1)
- Acute tryptophan depletion (1)
- Adult (1)
- Adult head (1)
- Ageing (1)
- Aggressive behaviour (1)
- Albino rat (1)
- Alzheimer disease (1)
- Alzheimer-Krankheit (1)
- Alzheimer’s dementia (1)
- Ankyrin (1)
- Antidepressants (1)
- Anxiety (1)
- Anxiety-like behavior (1)
- Association study (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Auditory pathway (1)
- Auditory targets (1)
- Axonal degeneration (1)
- B 37 CAG repeat locus (1)
- BDNF Val66Met (1)
- Balints-Syndrome (1)
- Beer-lambert law (1)
- Bias (1)
- Biomarke (1)
- Biomarkers (1)
- Blood-brain barrier (1)
- Body weight (1)
- Brain (1)
- Brain atrophy (1)
- Brain mappins (1)
- C(-1019)G polymorphism (1)
- C-reactive protein (1)
- CA3 (1)
- CA4 (1)
- CAPS (1)
- CDH13 (1)
- CDH13 Expression (1)
- CDH13 mRNA (1)
- CLN3 (1)
- CNS (1)
- CNV (1)
- CNVs (1)
- COMT VAL(158)MET polymorphism (1)
- CRH1 (1)
- CRISPR-Cas Systems (1)
- Cadherin (CDH13) (1)
- Cadherin-13 (CDH13) (1)
- Capillaries (1)
- Case-Control Studies (1)
- Caudate nucleus (1)
- Cerebellar nuclei (1)
- Cerebrolysin (1)
- Chronic disease (1)
- Chronic heart failure (1)
- Chronic stress (1)
- Clinical Genetics (1)
- Coffin-Lowry syndrome (1)
- Cognitive Therapy (1)
- Cognitive control (1)
- Cognitive decline (1)
- Covid-19 (1)
- D-amino acid oxidase activator (1)
- DAT (1)
- DNA Methylation (1)
- DNA damage (1)
- DNA methyltransferases (1)
- DNMT3A (1)
- DRD2 (1)
- De-novo (1)
- Diabetic polyneuropathy (1)
- Disease progression (1)
- Disease-modifying therapies (1)
- Disorders (1)
- Dorsolateral prefrontal cortex (1)
- Drosophila (1)
- Drosophila model (1)
- Drug development (1)
- Dynamic Causal Modeling (1)
- E3 ubiquitin ligase (1)
- EBM (1)
- Early-onset (1)
- Enrichment analysis (1)
- Epigenesis (1)
- Europe (1)
- Event-related potentials (1)
- Expression (1)
- FNIRS (1)
- Female (1)
- GABA (1)
- GABBR1 (1)
- GAD1 (1)
- GAP (1)
- GFAP (1)
- GHQ-28 (1)
- GLUT3 (1)
- GPCRs (1)
- GRN (1)
- GWAS (1)
- Generic questionnaire (1)
- Genetic (1)
- Genotype (1)
- Glial fibrillary acidic protein (1)
- Granular layer (1)
- HAND (1)
- HDBSCAN (1)
- HIV (1)
- Htr1a (1)
- Htr2a (1)
- Htr2c (1)
- Human CDH13 (1)
- Human behaviour (1)
- Human brain (1)
- Human entorhinal area (1)
- Humans (1)
- Huntington's disease . Human cerebral cortex (1)
- Hurst Exponent (1)
- ICT (1)
- IMpACT (1)
- Induced Pluripotent Stem Cells (1)
- Inflammatio (1)
- Insensitivity (1)
- Insulin Degrading Enzyme (1)
- Interferon-alpha (1)
- Japanese population (1)
- KFZA (1)
- Knock-out mice (1)
- LPHN3 (1)
- LPS (1)
- Latency (1)
- Lateralitity (1)
- Laterality (1)
- Leonhard cIassification (1)
- Leonhard classification (1)
- Long-term depression (1)
- MAPK signaling (1)
- MCPH1 (1)
- MRI (1)
- Maintenance treatment (1)
- Major depression (1)
- Mania (1)
- Measurement invariance (1)
- Media (1)
- Medicine (1)
- Memory dysfunction (1)
- Messenger-RNA (1)
- MiMIC (1)
- Model (1)
- Molecular biology (1)
- Molecular-genetics (1)
- Monoamine Oxidase/genetics (1)
- Monopolar depression (1)
- Mood disorders (1)
- Motor nerve biopsy (1)
- Mouse-brain (1)
- N170 (1)
- NCAM1 (1)
- NIRS (1)
- NPSR1 (1)
- NPU (1)
- Neostriatum (1)
- Nerve fibers (1)
- Nesplora Aquarium (1)
- Neuronal plasticity (1)
- Neurone number (1)
- Neurons (1)
- Neuropathy (1)
- Neuroprotection (1)
- Neurotrophic factors (1)
- Nissl stain (1)
- Npy (1)
- Npyr1 (1)
- Npyr2 (1)
- Nucleus accumbens (1)
- Ontogeny (1)
- Opioid receptor (1)
- P100 (1)
- P300 topography (1)
- PET-1 (1)
- PTSD (1)
- PYY3-36 (1)
- Panic Disorder/genetics (1)
- Panic Disorder/therapy (1)
- Parallel fiber synapses (1)
- Parkinson disease (1)
- Parkinsonism (1)
- Perinatal Asphyxia (1)
- Personalized medicine (1)
- Photon migration (1)
- Physiological functions (1)
- Pigmentarchitectonics (1)
- Polarity index (1)
- Predominant polarity (1)
- Prognostic markers (1)
- Propagation (1)
- Prosaccade (1)
- Psychisch Kranker (1)
- Qb-Test (1)
- Quetiapine (1)
- RIM1α (1)
- RNA expression (1)
- RSK (1)
- RSK2 (1)
- RTMS (1)
- Rat-brain (1)
- Regional differences (1)
- Restraint stress (1)
- Rotary EXcitation (REX) (1)
- Roux-en-Y gastric bypass surgery (1)
- S-HT (1)
- S6KII RSK (1)
- SARS-CoV-2 (1)
- SARS-CoV-2 brain disorders (1)
- SCF (1)
- SERT (1)
- SKP1 (1)
- SLC2A3 (1)
- SLC6A4 (1)
- STORM (1)
- SV pool (1)
- Saccadic eye-movements (1)
- Scattering (1)
- Schizophrenia (1)
- Schwangerschaft (1)
- Selective attention (1)
- Senescent rat (1)
- Senile rat (1)
- Senile rats (1)
- Sequence Analysis (1)
- Serotonin (1)
- Serotonin transporter (1)
- Serotonin transporter polymorphism (1)
- Sert-deficient mice (1)
- Skin biopsy (1)
- Sonic hedgehog (1)
- Spectroscopy fnirs (1)
- Spinal nerves (1)
- Spines (1)
- Stimuli (1)
- Strain differences (1)
- Striatum (1)
- Sub-saharan Africa (1)
- Surrogate endpoints (1)
- System (1)
- Systematic review (1)
- T-cadherin (1)
- Task-performance (1)
- Thalamic nuclei (1)
- Tissues (1)
- Toll-like receptor 4 (TLR4) (1)
- Transgenic mice (1)
- Transporter (1)
- Triple in situ hybridization (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- UPPS (1)
- Ultrastructure (1)
- Unc-13 (1)
- VAL66MET polymorphism (1)
- VBM (1)
- Vergence (1)
- Voluntary control (1)
- Western diet (1)
- Working memory (1)
- Xenopus laevis oocytes (1)
- accidents (1)
- acetylcholine (1)
- acid sphingomyelinase (1)
- acoustic startle (1)
- acute brain slices (1)
- acute mania (1)
- adolescence (1)
- adult attention deficit/hyperactivity disorder (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adult treatment (1)
- advisory groups (1)
- affective disorders (1)
- affective state (1)
- age stereotypes (1)
- aggressiveness (1)
- aging and cell death (1)
- aging brain (1)
- aging-related disease (1)
- agreeableness (1)
- allostatic load (1)
- amino acid analysis (1)
- amygdala response (1)
- analysis of variance (1)
- animal performance (1)
- anterior insula (1)
- anti-depressive treatment (1)
- anticipation (1)
- anticipatory anxiety (1)
- antidepressive agents (1)
- anxiety like (1)
- anxiety-like behavior (1)
- anxious depression (1)
- aphasia (1)
- apolipoprotein-E4 (1)
- apoptosis (1)
- assay (1)
- assessment of cognitive disorders/dementia (1)
- astrocytes (1)
- atlas‐based volumetry (1)
- atopic dermatitis (1)
- attention (1)
- attention deficit hyperactivity disorder (1)
- attention deficit/hyperactivity disorder (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- attentional bias (1)
- auditory cortex (1)
- autism (1)
- autism spectrum disorder (1)
- autism-like behavior (1)
- autoinhibition (1)
- awareness (1)
- axonal transport (1)
- basal ganglia (1)
- behavioral activation system (1)
- beside test (1)
- biased signaling (1)
- bipolar disorders (1)
- blood biomarker (1)
- bold (1)
- bold activity (1)
- brain activation (1)
- brain bank (1)
- brain derived neurotrophic factor (1)
- brain development (1)
- brain disorders (1)
- brain pathology (1)
- brain stem (1)
- brain stimulation (1)
- brain-regions (1)
- breast cancer (1)
- burden (1)
- cadherins (1)
- caffeine-induced anxiety (1)
- cancer (1)
- candidate gene (1)
- capacity (1)
- capecitabine (1)
- cardiac sympathetic nerve system (1)
- cardiology (1)
- cardiorespiratory centre (1)
- cardiovascular arousal (1)
- case fatality rates (1)
- cell membranes (1)
- cell proliferation (1)
- cells (1)
- ceramides (1)
- cerebellar ataxia (1)
- cerebellar atrophy (1)
- cerebral artery occlusion (1)
- cerebrospina (1)
- child development (1)
- child memory (1)
- childhood maltreatment (1)
- cholinergic neurons (1)
- chromosome 12 (1)
- chronic distress (1)
- chronic stress (1)
- classical conditioning (1)
- classification (1)
- clinical diagnosis (1)
- clinical practice guideline (1)
- clinical trial (1)
- coexpression (1)
- cognitive bias (1)
- cognitive control (1)
- cognitive decline (1)
- cognitive deficits (1)
- cognitive dysfunction (1)
- cognitive neuropsychology in dementia (1)
- cognitive-behavioral therapy (1)
- cognitive-behavioural psychotherapy (1)
- cohort studies (1)
- community sample (1)
- comparative anatomy (1)
- complementary alternative medicine (1)
- complex interventions (1)
- comprehensive psychosomatic assessment (1)
- computer-assisted instruction (1)
- congenital heart-deffects (1)
- contextual fear conditioning (1)
- continuous performance test (1)
- control strain (1)
- coping style (1)
- coping with challenge (1)
- copy number variants (1)
- copy number variation (1)
- copy-number variation (1)
- coronavirus (1)
- cortex (1)
- corticotropin releasing factor (1)
- cortisol (1)
- course (1)
- cross-sectional studies (1)
- cross-sectional study (1)
- crystal structure (1)
- cycloid psychoses (1)
- cytoarchitectonic maps (1)
- cytoarchitectonics (1)
- cytome biomarkers (1)
- damage (1)
- data mining (1)
- de-novo methylation (1)
- deaths (1)
- decision making (1)
- defensive reactivity (1)
- defensive system reactivity (1)
- deficient mice (1)
- deficit (1)
- deficit hyperactivity disorder (1)
- dehydrogenases (1)
- delay (1)
- dementia with Lewy bodies (1)
- depressive disorder (1)
- development (1)
- developmental delay (1)
- dexamethasone (1)
- diagnosis (1)
- diagnostic medicine (1)
- dictator game (1)
- diet (1)
- differentiation (1)
- digital phenotyping (1)
- dimensions (1)
- disability (1)
- discrimination training (1)
- disease modelling (1)
- disease-modifying therapies (1)
- dopaminergics (1)
- dorsal raphe nucleus (1)
- drift-diffusion modeling (1)
- drug development (1)
- drug-addiction (1)
- dual guidance (1)
- e-learning (1)
- early diagnosis (1)
- early intervention (1)
- early-life stress (1)
- early-onset predictors (1)
- ecological momentary assessment (1)
- ectodomain cleavage (1)
- egoism (1)
- elderly (1)
- electrode recording (1)
- electroeneephalography (1)
- electron tomography (1)
- embryos (1)
- emotional behavior (1)
- emotional experience (1)
- emotional influence (1)
- emotional information (1)
- emotions (1)
- encephalitis lethargica (1)
- endocannabinoids (1)
- endogenous psychoses (1)
- endophenotype (1)
- energy expenditure (1)
- energy metabolism (1)
- entorhinal cortex (1)
- environment (1)
- epigenetics in the nervous system (1)
- epigenomics (1)
- event-related fMRI (1)
- evoked potentials (1)
- executive function training (1)
- executive functions (1)
- eyes (1)
- facial affect (1)
- facial expression (1)
- factor expression (1)
- famiIiaI ·sporadic concept (1)
- familial-sporadic concept (1)
- families (1)
- family (1)
- family caregivers (1)
- fatigue (1)
- fear expression (1)
- fear learning (1)
- fear memory consolidation (1)
- fear-relevant training (1)
- febrile seizures (1)
- feedback (1)
- female (1)
- ferroptosis (1)
- fetal preconditioning (1)
- fibromyalgia syndrome (1)
- fluid (1)
- follow-up (1)
- freezing (1)
- frontal cortex (1)
- frontotemporal lobar degeneration (1)
- fumarate (1)
- functional near-infrared spectroscopy (1)
- fusiform gyrus (1)
- gender (1)
- gender differences (1)
- gene × gene interaction (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- geneexpression (1)
- genetic interaction (1)
- genetic loci (1)
- genetic phenotypes (1)
- genetic risk factor (1)
- genetic variants (1)
- genetic variation (1)
- genetics memory (1)
- genomic response (1)
- genotype (1)
- genotype-phenotype patterns (1)
- glia (1)
- glucocorticoids (1)
- glucose (1)
- glucose tolerance (1)
- glutamate (1)
- glutamate receptor (1)
- glycine (1)
- glycine receptor (1)
- glycine receptor beta subunit (1)
- glycogen synthase kinase-3β (1)
- granule cells (1)
- granules (1)
- growth factor (1)
- hand (1)
- haplotypes (1)
- head (1)
- health care (1)
- heart failure (1)
- heat shock protein Hsc-70 (1)
- hepcidin (1)
- heritability (1)
- heterosis (1)
- heterozygote (1)
- hierarchical drift-diffusion modeling (1)
- high-pressure freezing (1)
- hippocampal formation (1)
- hippocampal mossy fiber bouton (1)
- hippocampal neurogenesis (1)
- hippocampal volume (1)
- histamine (1)
- hospital (1)
- hospitalisation (1)
- human brain (1)
- human induced pluripotent stem cell (hiPSC) (1)
- human orbitofrontal cortex (1)
- hyperactivity (1)
- hypothalamic gene expression (1)
- iPSC (1)
- iiron transporter (1)
- imaging mass spectrometry (1)
- immediate-early gene (1)
- immunology (1)
- impact (1)
- impairments (1)
- impulse control disorders (1)
- impulsivity (1)
- in vivo (1)
- incentives (1)
- incidence (1)
- indans (1)
- individual differences (1)
- individual quality of life (1)
- inferior parietal lobule (1)
- inflammatory cytokines (1)
- inflammatory diseases (1)
- informal caregiving (1)
- insulin resistance (1)
- insulin-like growth factor 1 receptor (1)
- intelligibility (1)
- interleukin 6 (1)
- intermediate phenotype approach (1)
- interstitial duplications (1)
- intervention study (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- ischemic brain injury (1)
- ischemic stroke (1)
- joint action (1)
- judgement bias (1)
- knock-out mice (1)
- laboratory and online studies (1)
- laboratory environment (1)
- lacking (1)
- learning and memory (1)
- learning curves (1)
- length of stay (1)
- levodopa (1)
- life (1)
- linkage (1)
- liraglutide (1)
- lithium (1)
- localization microscopy (1)
- loci (1)
- locomotor activity (1)
- loneliness (1)
- longitudinal magnetic resonance imaging (1)
- machine learning (1)
- magnetic-resonance-spectroscopy (1)
- major depressive disorder (MDD) (1)
- mammalian development (1)
- management (1)
- mapping susceptibility genes (1)
- massively multiplayer online role playing games (1)
- maternal (1)
- maternal infection (1)
- maternal separation (1)
- matrix metalloproteinase (1)
- maturation (1)
- mechanismofaction (1)
- mechanisms (1)
- medial prefrontal cortex (mPFC) (1)
- medial temporal lobe (1)
- median and dorsal raphe (1)
- medical Education (1)
- medical education (1)
- medicine (1)
- membrane potential (1)
- membrane proteins (1)
- memory consolidation and extinction (1)
- memory deficits (1)
- memory formation (1)
- mental arithmetic (1)
- mental illness (1)
- messenger RNA (1)
- metaanalysis (1)
- metagenomics (1)
- methylphenidate (1)
- microarray (1)
- microarrays (1)
- microcephalin 1 (1)
- microdeletion (1)
- midbrain (1)
- middle aged (1)
- migraine (1)
- mild cognitive impairment (1)
- mind-body intervention (1)
- mismatch (1)
- mitochondria (1)
- mitochondrial pathology (1)
- mitochondrial translation (1)
- mitochondrial transport (1)
- mobile crowdsensing (1)
- mobile health (1)
- moclobemide (1)
- modulation (1)
- molecular genetics (1)
- monetary incentive delay task (1)
- monoamine oxidase (1)
- monoamine oxidase A (1)
- monoamine oxidase inhibitors (1)
- monoamine transporters (1)
- mood disorder (1)
- mood disorders (1)
- morality (1)
- mothers (1)
- motivation (1)
- motoneuron (1)
- mouse (1)
- movement disorders (1)
- mrsk2 KO mouse (1)
- multicenter (1)
- multimedia, (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multiple system atrophy (1)
- multi‑center cohort study (1)
- myocardial sympathetic innervation imaging (1)
- nanoarchitecture (1)
- neonatal brain (1)
- neonatal hypoxia (1)
- nervour system (1)
- nervous system (1)
- neural activity (1)
- neural fear network activation (1)
- neural mechanisms (1)
- neural stem cells (1)
- neuregulin-1 (1)
- neurite outgrowth (1)
- neurobiology (1)
- neurodevelopmental disorders (1)
- neurodevelopmental disorders / genetics (1)
- neurofilament light chain (1)
- neurogenesis (1)
- neuroinvasion (1)
- neurological disorders (1)
- neurological symptoms/disorders (1)
- neurology (1)
- neuromelanin granules (1)
- neuromuscular junction (1)
- neuron (1)
- neuron navigator 3 (1)
- neuronal dendrites (1)
- neuronal differentiation (1)
- neuronal dysfunction (1)
- neuronal plasticity (1)
- neurons (1)
- neuropathic pain (1)
- neuroplasticity (1)
- neuropsychiatry (1)
- neurorehabilitation (1)
- neuroscience (1)
- neurothrophic factor (1)
- neurotrophic factor (1)
- neurotrophic factor gene (1)
- nitricoxidesynthase (1)
- nucleus (1)
- nucleus accumbens (1)
- nurses (1)
- objective structured clinical examination (1)
- observer agreement (1)
- obstetric complications (1)
- of-the-literature (1)
- older employees (1)
- onset (1)
- optic ataxia (1)
- oral anticancer drugs (1)
- oscillating biomagnetic fields (1)
- oxygen consumption (1)
- parathyroid hormone 1 receptor (1)
- parent training (1)
- parental origin (1)
- parietal lobe (1)
- parkinson’s disease (1)
- paternal (1)
- patient-doctor-relationship (1)
- pediatrics (1)
- people (1)
- perception (1)
- periodic catatonia (1)
- peripheral-blood lymphocytes (1)
- persistent ADHD (1)
- personality (1)
- personalized medicine (1)
- perspectives (1)
- pharmacogenetics (1)
- pharmacotherapy (1)
- pharmacovigilance (1)
- phasic threat responding (1)
- phenelzine (1)
- phobia (1)
- phosphorylated tau protein (1)
- physical health (1)
- pigment (1)
- polymorphism (1)
- polymorphisms (1)
- population (1)
- population-based studies (1)
- positive affect (1)
- positive interneurons (1)
- positron-emission-tomography (1)
- postencephalitic parkinsonism (1)
- posterior cortical atrophy (1)
- posterior parietal cortex (1)
- posteroinferior occipitotemporal gyrus (1)
- postmortem (1)
- postmortem studies (1)
- postnatal depression (1)
- posttraumatic-stress-disorder (1)
- precision medicine (1)
- predict (1)
- prefrontal activity (1)
- pregnancy anxiety (1)
- prenatal stress (1)
- prepulse inhibition (1)
- presynaptic (1)
- presynaptic homeostasis (1)
- prevalence (1)
- prevention (1)
- preventive strategies (1)
- primary care (1)
- primary progressive aphasia (1)
- primary response genes (1)
- process evaluation (1)
- processing bias (1)
- processing speed (1)
- proliferation (1)
- promoter region (1)
- prophylactic lithium (1)
- prosociality (1)
- protein (1)
- protein aggregation (1)
- protein kinase (1)
- psychiatric-hospitalization (1)
- psycho-geriatrics (1)
- psychological distress (1)
- psychological stress (1)
- psychology (1)
- psychooncology (1)
- psychopathology (1)
- psychosocial stress (1)
- psychosocial workplace risk assessment (1)
- psychotic experiences (1)
- psychotropic medication (1)
- psychotropic medications (1)
- public health (1)
- punishment (1)
- qualitative approaches (1)
- quality of live (1)
- quantitative anatomy (1)
- randomized-controlled trial (1)
- rare diseases (1)
- rare mendelian disorders (1)
- rasagiline (1)
- rat brain (1)
- rating scale (1)
- real-life interaction (1)
- realist evaluation (1)
- receptor gene polymorphism (1)
- receptors (1)
- recognition memory (1)
- reconsolidation (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- regenerative research (1)
- religiosity (1)
- remitted/acute phase (1)
- renal function (1)
- repair (1)
- repulsive guidance molecule A (1)
- research errors (1)
- resting-state fMRI (1)
- reward (1)
- reward deficiency syndrome (1)
- right inferior frontalgyrus (1)
- risk genes (1)
- risperidone (1)
- rule discovery (1)
- safety (1)
- safety behavior (1)
- sample size calculation (1)
- sections (1)
- selegiline (1)
- self-employed (1)
- sequence variations (1)
- serotonergic system (1)
- serotonin deficiency (1)
- serotonin receptors (1)
- serotonin transporter deficient mice (1)
- serotonin(1A) receptor (1)
- serotonin-specific neurons (1)
- serum concentration (1)
- sex (1)
- short-term methylphenidate brain (1)
- short-term-memory (1)
- sialic acid (1)
- sialyltransferase (1)
- signal transduction pathway (1)
- simulation (1)
- single subject (1)
- skin conductance (1)
- skin conduction response (1)
- small business (1)
- smoking cessation (1)
- social anxiety (1)
- social avoidance (1)
- social capital (1)
- social cognitive (1)
- social distancing (1)
- social experience (1)
- social interaction (1)
- social isolation (1)
- social motives (1)
- social neuroscience (1)
- spastic (1)
- spatial memory (1)
- spectrum disorder (1)
- spectrum disorders (1)
- sphingolipids (1)
- spider phobia (1)
- spontaneously hypertensive rat (1)
- sporadic Parkinson's disease (1)
- startle reaction (1)
- states (1)
- stem cells (1)
- stereology (1)
- strategies (1)
- streptozotocin (1)
- stress granules (1)
- stressful life events (1)
- stroop interference (1)
- subphenotypes (1)
- subsctraction (1)
- subsequent memory (1)
- supervisors (1)
- surrogate endpoints (1)
- survey (1)
- susceptibility (1)
- sustained fear (1)
- sustained threat responding (1)
- swim test (1)
- synapse (1)
- synapse formation (1)
- synaptic plasticity (1)
- synaptic transmission (1)
- synaptic ultrastructure (1)
- synaptosomes (1)
- systems (1)
- systems biology (1)
- tDCS (1)
- tandem mass spectrometry (1)
- target (1)
- targeted bisulfite sequencing (1)
- task complexity (1)
- task difficulty (1)
- tauopathy (1)
- teaching hospital (1)
- telomere length (1)
- temporal lobe epilepsy (1)
- theranostic markers (1)
- therapeutic drug monitoring (1)
- therapy (1)
- therapy response (1)
- threat-related stimuli (1)
- tolerability (1)
- tolerance (1)
- trail making test (1)
- transcranial magnetic stimulation (1)
- transcranial magnetic stimulation (TMS) (1)
- transient global ischemia (1)
- transmission (1)
- transporter gene SLC2A3 (1)
- tranylcypromine (1)
- treatment (1)
- treatment guidelines (1)
- treatment response (1)
- tryptophan hydroxylase 2 (1)
- tryptophan hydroxylase-2 (1)
- ubiquitination (1)
- ultra-high risk (1)
- ultrasound imaging (1)
- understaffed (1)
- valence framing (1)
- validation (1)
- validity (1)
- ventromedial prefrontal cortex (1)
- verbal fluency task (1)
- verbal n-back (1)
- video-game (1)
- virtual patients (1)
- viruses (1)
- virus–iron interaction (1)
- vitamin D deficiency (1)
- volumetric MRI (1)
- von Economo (1)
- voxel-based morphometry (1)
- work-related stress (1)
- world of warcraft (1)
- yoga (1)
- younger employees (1)
- ɑ-Synuclein and iron (1)
Institute
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (234) (remove)
Sonstige beteiligte Institutionen
Objectives
The pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS.
Methods
Sixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis.
Results
Quantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (p<0.05), but not different from that of patients with depression and accompanying physical pain. Pain and FMS symptom burden did not correlate with midbrain raphe echogenicity as well as the presence and severity of depressive symptoms.
Conclusion
We found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression.
Background
Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain and associated symptoms. We investigated cerebral activation in FMS patients by functional near-infrared spectroscopy (fNIRS).
Methods
Two stimulation paradigms were applied: a) painful pressure stimulation at the dorsal forearm; b) verbal fluency test (VFT). We prospectively recruited 25 FMS patients, ten patients with unipolar major depression (MD) without pain, and 35 healthy controls. All patients underwent neurological examination and all subjects were investigated with questionnaires (pain, depression, FMS, empathy).
Results
FMS patients had lower pressure pain thresholds than patients with MD and controls (p < 0.001) and reported higher pain intensity (p < 0.001). Upon unilateral pressure pain stimulation fNIRS recordings revealed increased bilateral cortical activation in FMS patients compared to controls (p < 0.05). FMS patients also displayed a stronger contralateral activity over the dorsolateral prefrontal cortex in direct comparison to patients with MD (p < 0.05). While all three groups performed equally well in the VFT, a frontal deficit in cortical activation was only found in patients with depression (p < 0.05). Performance and cortical activation correlated negatively in FMS patients (p < 0.05) and positively in patients with MD (p < 0.05).
Conclusion
Our data give further evidence for altered central nervous processing in patients with FMS and the distinction between FMS and MD.
Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls
(2014)
Background
Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization.
Methods
We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as housekeeping gene. Additionally, we assessed DOR gene expression.
Results
All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and lower leg within and between the groups and in FMS patient subgroups.
Conclusions
Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential mechanism of small fiber pathology in FMS.
Copy number variants of SLC2A3, which encodes the glucose transporter GLUT3, are associated with several neuropsychiatric and cardiac diseases. Here, we report the successful reprogramming of peripheral blood mononuclear cells from two SLC2A3 duplication and two SLC2A3 deletion carriers and subsequent generation of two transgene-free iPSC clones per donor by Sendai viral transduction. All eight clones represent bona fide hiPSCs with high expression of pluripotency genes, ability to differentiate into cells of all three germ layers and normal karyotype. The generated cell lines will be helpful to enlighten the role of glucometabolic alterations in pathophysiological processes shared across organ boundaries.
The cell—cell signaling gene CDH13 is associated with a wide spectrum of neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), autism, and major depression. CDH13 regulates axonal outgrowth and synapse formation, substantiating its relevance for neurodevelopmental processes. Several studies support the influence of CDH13 on personality traits, behavior, and executive functions. However, evidence for functional effects of common gene variation in the CDH13 gene in humans is sparse. Therefore, we tested for association of a functional intronic CDH13 SNP rs2199430 with ADHD in a sample of 998 adult patients and 884 healthy controls. The Big Five personality traits were assessed by the NEO-PI-R questionnaire. Assuming that altered neural correlates of working memory and cognitive response inhibition show genotype-dependent alterations, task performance and electroencephalographic event-related potentials were measured by n-back and continuous performance (Go/NoGo) tasks. The rs2199430 genotype was not associated with adult ADHD on the categorical diagnosis level. However, rs2199430 was significantly associated with agreeableness, with minor G allele homozygotes scoring lower than A allele carriers. Whereas task performance was not affected by genotype, a significant heterosis effect limited to the ADHD group was identified for the n-back task. Heterozygotes (AG) exhibited significantly higher N200 amplitudes during both the 1-back and 2-back condition in the central electrode position Cz. Consequently, the common genetic variation of CDH13 is associated with personality traits and impacts neural processing during working memory tasks. Thus, CDH13 might contribute to symptomatic core dysfunctions of social and cognitive impairment in ADHD.
SLC2A3 encodes the predominantly neuronal glucose transporter 3 (GLUT3), which facilitates diffusion of glucose across plasma membranes. The human brain depends on a steady glucose supply for ATP generation, which consequently fuels critical biochemical processes, such as axonal transport and neurotransmitter release. Besides its role in the central nervous system, GLUT3 is also expressed in nonneural organs, such as the heart and white blood cells, where it is equally involved in energy metabolism. In cancer cells, GLUT3 overexpression contributes to the Warburg effect by answering the cell's increased glycolytic demands. The SLC2A3 gene locus at chromosome 12p13.31 is unstable and prone to non‐allelic homologous recombination events, generating multiple copy number variants (CNVs) of SLC2A3 which account for alterations in SLC2A3 expression. Recent associations of SLC2A3 CNVs with different clinical phenotypes warrant investigation of the potential influence of these structural variants on pathomechanisms of neuropsychiatric, cardiovascular, and immune diseases. In this review, we accumulate and discuss the evidence how SLC2A3 gene dosage may exert diverse protective or detrimental effects depending on the pathological condition. Cellular states which lead to increased energetic demand, such as organ development, proliferation, and cellular degeneration, appear particularly susceptible to alterations in SLC2A3 copy number. We conclude that better understanding of the impact of SLC2A3 variation on disease etiology may potentially provide novel therapeutic approaches specifically targeting this GLUT.
Epigenetic signatures such as methylation of the monoamine oxidase A (MAOA) gene have been found to be altered in panic disorder (PD). Hypothesizing temporal plasticity of epigenetic processes as a mechanism of successful fear extinction, the present psychotherapy-epigenetic study for we believe the first time investigated MAOA methylation changes during the course of exposure-based cognitive behavioral therapy (CBT) in PD. MAOA methylation was compared between N=28 female Caucasian PD patients (discovery sample) and N=28 age- and sex-matched healthy controls via direct sequencing of sodium bisulfite-treated DNA extracted from blood cells. MAOA methylation was furthermore analyzed at baseline (T0) and after a 6-week CBT (T1) in the discovery sample parallelized by a waiting time in healthy controls, as well as in an independent sample of female PD patients (N=20). Patients exhibited lower MAOA methylation than healthy controls (P<0.001), and baseline PD severity correlated negatively with MAOA methylation (P=0.01). In the discovery sample, MAOA methylation increased up to the level of healthy controls along with CBT response (number of panic attacks; T0-T1: +3.37±2.17%), while non-responders further decreased in methylation (-2.00±1.28%; P=0.001). In the replication sample, increases in MAOA methylation correlated with agoraphobic symptom reduction after CBT (P=0.02-0.03). The present results support previous evidence for MAOA hypomethylation as a PD risk marker and suggest reversibility of MAOA hypomethylation as a potential epigenetic correlate of response to CBT. The emerging notion of epigenetic signatures as a mechanism of action of psychotherapeutic interventions may promote epigenetic patterns as biomarkers of lasting extinction effects.
Purpose
Examine the effects of an 8-week yoga therapy on fatigue in patients with different types of cancer.
Methods
A total of 173 cancer patients suffering from mild to severe fatigue were randomly allocated to yoga intervention (n = 84) (IG) versus waitlist control group (CG) (n = 88). Yoga therapy consisted of eight weekly sessions with 60 min each. The primary outcome was self-reported fatigue symptoms. Secondary outcomes were symptoms of depression and quality of life (QoL). Data were assessed using questionnaires before (T0) and after yoga therapy for IG versus waiting period for CG (T1).
Results
A stronger reduction of general fatigue (P = .033), physical fatigue (P = .048), and depression (P < .001) as well as a stronger increase in QoL (P = .002) was found for patients who attended 7 or 8 sessions compared with controls. Within the yoga group, both higher attendance rate and lower T0-fatigue were significant predictors of lower T1-fatigue (P ≤ .001). Exploratory results revealed that women with breast cancer report a higher reduction of fatigue than women with other types of cancer (P = .016) after yoga therapy.
Conclusion
The findings support the assumption that yoga therapy is useful to reduce cancer-related fatigue, especially for the physical aspects of fatigue. Women with breast cancer seem to benefit most, and higher attendance rate results in greater reduction of fatigue.
Trial registration
German Clinical Trials Register DRKS00016034
Depression is a common psychiatric disorder among geriatric patients that decreases the quality of life and increases morbidity and mortality. Vitamin D as a neuro-steroid hormone might play a role in the onset and treatment of depression. In the present study, the association between depressive symptoms and vitamin D concentration in serum was evaluated. 140 patients of a psychogeriatric day-care unit were included. The geriatric depression scale (GDS) and the Hamilton depression rating scale (HDRS) were assessed at the beginning and end of treatment, GDS scores additionally 6 weeks after discharge from the day-care unit. Vitamin D levels were measured at the beginning of the treatment, routinely. Patients with levels below 30 µg/L were treated with 1000 IU vitamin D per day. There was no association between the severity of depressive symptoms and the concentration of vitamin D at the beginning of the treatment. Patients with higher vitamin D levels showed a stronger decline of depressive symptoms measured by the GDS during their stay in the day-care unit. We provide evidence that vitamin D serum levels might influence antidepressant therapy response in a geriatric population. Prospective studies are necessary to determine which patients may profit from add-on vitamin D therapy.
Background
Chronic psychological stress is associated with accelerated aging and increased risk for aging-related diseases, but the underlying molecular mechanisms are unclear.
Results
We examined the effect of lifetime stressors on a DNA methylation-based age predictor, epigenetic clock. After controlling for blood cell-type composition and lifestyle parameters, cumulative lifetime stress, but not childhood maltreatment or current stress alone, predicted accelerated epigenetic aging in an urban, African American cohort (n = 392). This effect was primarily driven by personal life stressors, was more pronounced with advancing age, and was blunted in individuals with higher childhood abuse exposure. Hypothesizing that these epigenetic effects could be mediated by glucocorticoid signaling, we found that a high number (n = 85) of epigenetic clock CpG sites were located within glucocorticoid response elements. We further examined the functional effects of glucocorticoids on epigenetic clock CpGs in an independent sample with genome-wide DNA methylation (n = 124) and gene expression data (n = 297) before and after exposure to the glucocorticoid receptor agonist dexamethasone. Dexamethasone induced dynamic changes in methylation in 31.2 % (110/353) of these CpGs and transcription in 81.7 % (139/170) of genes neighboring epigenetic clock CpGs. Disease enrichment analysis of these dexamethasone-regulated genes showed enriched association for aging-related diseases, including coronary artery disease, arteriosclerosis, and leukemias.
Conclusions
Cumulative lifetime stress may accelerate epigenetic aging, an effect that could be driven by glucocorticoid-induced epigenetic changes. These findings contribute to our understanding of mechanisms linking chronic stress with accelerated aging and heightened disease risk.
This study investigated the role of bottom-up and top-down neural mechanisms in the processing of emotional face expression during memory formation. Functional brain imaging data was acquired during incidental learning of positive ("happy"), neutral and negative ("angry" or "fearful") faces. Dynamic Causal Modeling (DCM) was applied on the functional magnetic resonance imaging (fMRI) data to characterize effective connectivity within a brain network involving face perception (inferior occipital gyrus and fusiform gyrus) and successful memory formation related areas (hippocampus, superior parietal lobule, amygdala, and orbitofrontal cortex). The bottom-up models assumed processing of emotional face expression along feed forward pathways to the orbitofrontal cortex. The top-down models assumed that the orbitofrontal cortex processed emotional valence and mediated connections to the hippocampus. A subsequent recognition memory test showed an effect of negative emotion on the response bias, but not on memory performance. Our DCM findings showed that the bottom-up model family of effective connectivity best explained the data across all subjects and specified that emotion affected most bottom-up connections to the orbitofrontal cortex, especially from the occipital visual cortex and superior parietal lobule. Of those pathways to the orbitofrontal cortex the connection from the inferior occipital gyrus correlated with memory performance independently of valence. We suggest that bottom-up neural mechanisms support effects of emotional face expression and memory formation in a parallel and partially overlapping fashion.
Neuromelanin granules (NMGs) are organelle-like structures present in the human substantia nigra pars compacta. In addition to neuromelanin, NMGs contain proteins, lipids and metals. As NMG-containing dopaminergic neurons are preferentially lost in Parkinson’s disease and dementia with Lewy bodies (DLB), it is assumed that NMGs may play a role in neurodegenerative processes. Until now, this role is not completely understood and needs further investigation. We therefore set up an exploratory proteomic study to identify differences in the proteomic profile of NMGs from DLB patients (n = 5) compared to healthy controls (CTRL, n = 5). We applied a laser microdissection and mass-spectrometry-based approach, in which we used targeted mass spectrometric experiments for validation. In NMG-surrounding (SN\(_{Surr.}\)) tissue of DLB patients, we found evidence for ongoing oxidative damage and an impairment of protein degradation. As a potentially disease-related mechanism, we found α-synuclein and protein S100A9 to be enriched in NMGs of DLB cases, while the abundance of several ribosomal proteins was significantly decreased. As S100A9 is known to be able to enhance the formation of toxic α-synuclein fibrils, this finding points towards an involvement of NMGs in pathogenesis, however the exact role of NMGs as either neuroprotective or neurotoxic needs to be further investigated. Nevertheless, our study provides evidence for an impairment of protein degradation, ongoing oxidative damage and accumulation of potentially neurotoxic protein aggregates to be central mechanisms of neurodegeneration in DLB.
Previous studies consistently reported abnormal recognition of facial expressions in depression. However, it is still not clear whether this abnormality is due to an enhanced or impaired ability to recognize facial expressions, and what underlying cognitive systems are involved. The present study aimed to examine how individuals with elevated levels of depressive symptoms differ from controls on facial expression recognition and to assess attention and information processing using eye tracking. Forty participants (18 with elevated depressive symptoms) were instructed to label facial expressions depicting one of seven emotions. Results showed that the high-depression group, in comparison with the low-depression group, recognized facial expressions faster and with comparable accuracy. Furthermore, the high-depression group demonstrated greater leftwards attention bias which has been argued to be an indicator of hyperactivation of right hemisphere during facial expression recognition.
Occurrence of mental illness and mental health risks among the self-employed: a systematic review
(2021)
We aimed to systematically identify and evaluate all studies of good quality that compared the occurrence of mental disorders in the self-employed versus employees. Adhering to the Cochrane guidelines, we conducted a systematic review and searched three major medical databases (MEDLINE, Web of Science, Embase), complemented by hand search. We included 26 (three longitudinal and 23 cross-sectional) population-based studies of good quality (using a validated quality assessment tool), with data from 3,128,877 participants in total. The longest of these studies, a Swedish national register evaluation with 25 years follow-up, showed a higher incidence of mental illness among the self-employed compared to white-collar workers, but a lower incidence compared to blue-collar workers. In the second longitudinal study from Sweden the self-employed had a lower incidence of mental illness compared to both blue- and white-collar workers over 15 years, whereas the third longitudinal study (South Korea) did not find a difference regarding the incidence of depressive symptoms over 6 years. Results from the cross-sectional studies showed associations between self-employment and poor general mental health and stress, but were inconsistent regarding other mental outcomes. Most studies from South Korea found a higher prevalence of mental disorders among the self-employed compared to employees, whereas the results of cross-sectional studies from outside Asia were less consistent. In conclusion, we found evidence from population-based studies for a link between self-employment and increased risk of mental illness. Further longitudinal studies are needed examining the potential risk for the development of mental disorders in specific subtypes of the self-employed.
Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3\(^+\) regulatory T-cell frequencies among CD4\(^+\) T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4\(^+\) Foxp3\(^+\) regulatory T-cell frequencies in humans. Pharmacological acid sphingomyelinase inhibition with antidepressants like sertraline, but not those without an inhibitory effect on acid sphingomyelinase activity like citalopram, increased the frequency of Foxp3\(^+\) regulatory T cell among human CD4\(^+\) T cells in vitro. In an observational prospective clinical study with patients suffering from major depression, we observed that acid sphingomyelinase-inhibiting antidepressants induced a stronger relative increase in the frequency of CD4\(^+\) Foxp3\(^+\) regulatory T cells in peripheral blood than acid sphingomyelinase-non- or weakly inhibiting antidepressants. This was particularly true for CD45RA\(^-\) CD25\(^{high}\) effector CD4\(^+\) Foxp3\(^+\) regulatory T cells. Mechanistically, our data indicate that the positive effect of acid sphingomyelinase inhibition on CD4\(^+\) Foxp3\(^+\) regulatory T cells required CD28 co-stimulation, suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Foxp3+ regulatory T cells among human CD4\(^+\) T cells. In summary, the widely induced pharmacological inhibition of acid sphingomyelinase activity in patients leads to an increase in Foxp3+ regulatory T-cell frequencies among CD4\(^+\) T cells in humans both in vivo and in vitro.
Background
Epigenetic mechanisms may play a major role in the biological embedding of early-life stress (ELS). One proposed mechanism is that glucocorticoid (GC) release following ELS exposure induces long-lasting alterations in DNA methylation (DNAm) of important regulatory genes of the stress response. Here, we investigate the dynamics of GC-dependent methylation changes in key regulatory regions of the FKBP5 locus in which ELS-associated DNAm changes have been reported.
Results
We repeatedly measured DNAm in human peripheral blood samples from 2 independent cohorts exposed to the GC agonist dexamethasone (DEX) using a targeted bisulfite sequencing approach, complemented by data from Illumina 450K arrays. We detected differentially methylated CpGs in enhancers co-localizing with GC receptor binding sites after acute DEX treatment (1 h, 3 h, 6 h), which returned to baseline levels within 23 h. These changes withstood correction for immune cell count differences. While we observed main effects of sex, age, body mass index, smoking, and depression symptoms on FKBP5 methylation levels, only the functional FKBP5 SNP (rs1360780) moderated the dynamic changes following DEX. This genotype effect was observed in both cohorts and included sites previously shown to be associated with ELS.
Conclusion
Our study highlights that DNAm levels within regulatory regions of the FKBP5 locus show dynamic changes following a GC challenge and suggest that factors influencing the dynamics of this regulation may contribute to the previously reported alterations in DNAm associated with current and past ELS exposure.
Background: \(^{123}\)I-metaiodobenzylguanidine (mIBG) provides independent prognostic value for risk stratification among heart failure patients, but the use of concomitant medication should not impact its quantitative information. We aimed to evaluate the four most-prescribed antidepressants currently used as a first‑line treatment for patients with major depressive disorder (MDD) and their potential on altering mIBG imaging results.
Methods: The inhibition effect of four different types of antidepressants (desipramine, escitalopram, venlafaxine and bupropion) for MDD treatment on \(^{131}\)I-mIBG uptake was assessed by in-vitro cell uptake assays using human neuroblastoma SK-N-SH cells. The half maximal inhibitory concentration (IC50) of tracer uptake was determined from dose-response curves. To evaluate the effects of IV pretreatment with desipramine (1.5 mg/kg) and escitalopram (2.5, 15 mg/kg) on mIBG cardiac uptake, in-vivo planar 123I-mIBG scans in healthy New Zealand White Rabbits were conducted. Results: The IC50 values of desipramine, escitalopram, venlafaxine and bupropion on \(^{131}\)I-mIBG cellular uptake were 11.9 nM, 7.5 μM, 4.92 μM, and 12.9 μM, respectively. At the maximum serum concentration (Cmax, as derived by previous clinical trials), the inhibition rates of 131I-mIBG uptake were 90.6 % for desipramine, 25.5 % for venlafaxine, 11.7 % for bupropion and 0.72 % for escitalopram. A low inhibition rate for escitalopram in the cell uptake study triggered investigation of an in-vivo rabbit model: with dosage considerably higher than clinical practice, the non-inhibitory effect of escitalopram was confirmed. Furthermore, pretreatment with desipramine led to a marked reduction of cardiac 123I-mIBG uptake.
Conclusions: In the present in-vitro binding assay and in-vivo rabbit study, the selective-serotonin reuptake inhibitor escitalopram had no major impact on neuronal cardiac mIBG uptake within therapeutic dose ranges, while other types of first-line antidepressants for MDD treatment led to a significant decrease. These preliminary results warrant further confirmatory clinical trials regarding the reliability of cardiac mIBG imaging, in particular, if the patient’s neuropsychiatric status would not tolerate withdrawal of a potentially norepinephrine interfering antidepressant.
To slow down the spread of the SARS-Cov-2 virus, countries worldwide severely restricted public and social life. In addition to the physical threat posed by the viral disease (COVID-19), the pandemic also has implications for psychological well-being. Using a small sample (N = 51), we examined how Big Five personality traits relate to coping with contact restrictions during three consecutive weeks in the first wave of the COVID-19 pandemic in Germany. We showed that extraversion was associated with suffering from severe contact restrictions and with benefiting from their relaxation. Individuals with high neuroticism did not show a change in their relatively poor coping with the restrictions over time, whereas conscientious individuals seemed to experience no discomfort and even positive feelings during the period of contact restrictions. Our results support the assumption that neuroticism is a vulnerability factor in relation to psychological wellbeing but also show an influence of contact restrictions on extraverted individuals.
Despite its negative reputation, egoism – the excessive concern for one’s own welfare – can incite prosocial behavior. So far, however, egoism-based prosociality has received little attention. Here, we first provide an overview of the conditions under which egoism turns into a prosocial motive, review the benefits and limitations of egoism-based prosociality, and compare them with empathy-driven prosocial behavior. Second, we summarize studies investigating the neural processing of egoism-based prosocial decisions, studies investigating the neural processing of empathy-based prosocial decisions, and the small number of studies that compared the neural processing of prosocial decisions elicited by the different motives. We conclude that there is evidence for differential neural networks involved in egoism and empathy-based prosocial decisions. However, this evidence is not yet conclusive, because it is mainly based on the comparison of different experimental paradigms which may exaggerate or overshadow the effect of the different motivational states. Finally, we propose paradigms and research questions that should be tackled in future research that could help to specify how egoism can be used to enhance other prosocial behavior and motivation, and the how it could be tamed.
In human interactions, the facial expression of a bargaining partner may contain relevant information that affects prosocial decisions. We were interested in whether facial expressions of the recipient in the dictator game influence dictators´ ehavior. To test this, we conducted an online study (n = 106) based on a modified version of a dictator game. The dictators allocated money between themselves and another person (recipient), who had no possibility to respond to the dictator.
Importantly, before the allocation decision, the dictator was presented with the facial expression of the recipient (angry, disgusted, sad, smiling, or neutral). The results showed that dictators sent more money to recipients with sad or smiling facial expressions and less to recipients with angry or disgusted facial expressions compared with a neutral facial expression. Moreover, based on the sequential analysis of the decision and the interaction partner in the preceding trial, we found that decision-making depends upon previous interactions.
Psychosocial factors affect mental health and health-related quality of life (HRQL) in a complex manner, yet gender differences in these interactions remain poorly understood. We investigated whether psychosocial factors such as social support and personal and work-related concerns impact mental health and HRQL differentially in women and men during the first year of the COVID-19 pandemic. Between June and October 2020, the first part of a COVID-19-specific program was conducted within the “Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB)” cohort study, a representative age- and gender-stratified sample of the general population of Würzburg, Germany. Using psychometric networks, we first established the complex relations between personal social support, personal and work-related concerns, and their interactions with anxiety, depression, and HRQL. Second, we tested for gender differences by comparing expected influence, edge weight differences, and stability of the networks. The network comparison revealed a significant difference in the overall network structure. The male (N = 1370) but not the female network (N = 1520) showed a positive link between work-related concern and anxiety. In both networks, anxiety was the most central variable. These findings provide further evidence that the complex interplay of psychosocial factors with mental health and HRQL decisively depends on gender. Our results are relevant for the development of gender-specific interventions to increase resilience in times of pandemic crisis.
Converging evidence suggests a role of serotonin (5-hydroxytryptamine, 5-HT) and tryptophan hydroxylase 2 (TPH2), the rate-limiting enzyme of 5-HT synthesis in the brain, in modulating long-term, neurobiological effects of early-life adversity. Here, we aimed at further elucidating the molecular mechanisms underlying this interaction, and its consequences for socio-emotional behaviors, with a focus on anxiety and social interaction. In this study, adult, male Tph2 null mutant (Tph2\(^{-/-}\)) and heterozygous (Tph2\(^{+/-}\)) mice, and their wildtype littermates (Tph2\(^{+/+}\)) were exposed to neonatal, maternal separation (MS) and screened for behavioral changes, followed by genome-wide RNA expression and DNA methylation profiling. In Tph2\(^{-/-}\) mice, brain 5-HT deficiency profoundly affected socio-emotional behaviors, i.e., decreased avoidance of the aversive open arms in the elevated plus-maze (EPM) as well as decreased prosocial and increased rule breaking behavior in the resident-intruder test when compared to their wildtype littermates. Tph2\(^{+/-}\) mice showed an ambiguous profile with context-dependent, behavioral responses. In the EPM they showed similar avoidance of the open arm but decreased prosocial and increased rule breaking behavior in the resident-intruder test when compared to their wildtype littermates. Notably, MS effects on behavior were subtle and depended on the Tph2 genotype, in particular increasing the observed avoidance of EPM open arms in wildtype and Tph2\(^{+/-}\) mice when compared to their Tph2\(^{-/-}\) littermates. On the genomic level, the interaction of Tph2 genotype with MS differentially affected the expression of numerous genes, of which a subset showed an overlap with DNA methylation profiles at corresponding loci. Remarkably, changes in methylation nearby and expression of the gene encoding cholecystokinin, which were inversely correlated to each other, were associated with variations in anxiety-related phenotypes. In conclusion, next to various behavioral alterations, we identified gene expression and DNA methylation profiles to be associated with TPH2 inactivation and its interaction with MS, suggesting a gene-by-environment interaction-dependent, modulatory function of brain 5-HT availability.
Background: Panic disorder is common (5% prevalence) and females are twice as likely to be affected as males. The heritable component of panic disorder is estimated at 48%. Glutamic acid dehydrogenase GAD1, the key enzyme for the synthesis of the inhibitory and anxiolytic neurotransmitter GABA, is supposed to influence various mental disorders, including mood and anxiety disorders. In a recent association study in depression, which is highly comorbid with panic disorder, GAD1 risk allele associations were restricted to females. Methodology/Principal Findings: Nineteen single nucleotide polymorphisms (SNPs) tagging the common variation in GAD1 were genotyped in two independent gender and age matched case-control samples (discovery sample n = 478; replication sample n = 584). Thirteen SNPs passed quality control and were examined for gender-specific enrichment of risk alleles associated with panic disorder by using logistic regression including a genotype6gender interaction term. The latter was found to be nominally significant for four SNPs (rs1978340, rs3762555, rs3749034, rs2241165) in the discovery sample; of note, the respective minor/risk alleles were associated with panic disorder only in females. These findings were not confirmed in the replication sample; however, the genotype6gender interaction of rs3749034 remained significant in the combined sample. Furthermore, this polymorphism showed a nominally significant association with the Agoraphobic Cognitions Questionnaire sum score. Conclusions/Significance: The present study represents the first systematic evaluation of gender-specific enrichment of risk alleles of the common SNP variation in the panic disorder candidate gene GAD1. Our tentative results provide a possible explanation for the higher susceptibility of females to panic disorder.
Objectives
Posttraumatic stress disorder (PTSD) is triggered by extremely stressful environmental events and characterized by high emotional distress, re-experiencing of trauma, avoidance and hypervigilance. The present study uses polygenic risk scores (PRS) derived from the UK Biobank (UKBB) mega-cohort analysis as part of the PGC PTSD GWAS effort to determine the heritable basis of PTSD in the South Eastern Europe (SEE)-PTSD cohort. We further analyzed the relation between PRS and additional disease-related variables, such as number and intensity of life events, coping, sex and age at war on PTSD and CAPS as outcome variables.
Methods
Association of PRS, number and intensity of life events, coping, sex and age on PTSD were calculated using logistic regression in a total of 321 subjects with current and remitted PTSD and 337 controls previously subjected to traumatic events but not having PTSD. In addition, PRS and other disease-related variables were tested for association with PTSD symptom severity, measured by the Clinician Administrated PTSD Scale (CAPS) by liner regression. To assess the relationship between the main outcomes PTSD diagnosis and symptom severity, each of the examined variables was adjusted for all other PTSD related variables.
Results
The categorical analysis showed significant polygenic risk in patients with remitted PTSD and the total sample, whereas no effects were found on symptom severity. Intensity of life events as well as the individual coping style were significantly associated with PTSD diagnosis in both current and remitted cases. The dimensional analyses showed as association of war-related frequency of trauma with symptom severity, whereas the intensity of trauma yielded significant results independently of trauma timing in current PTSD.
Conclusions
The present PRS application in the SEE-PTSD cohort confirms modest but significant polygenic risk for PTSD diagnosis. Environmental factors, mainly the intensity of traumatic life events and negative coping strategies, yielded associations with PTSD both categorically and dimensionally with more significant p-values. This suggests that, at least in the present cohort of war-related trauma, the association of environmental factors and current individual coping strategies with PTSD psychopathology was stronger than the polygenic risk.
Brain serotonin (5-hydroxytryptamine, 5-HT) system dysfunction is implicated in exaggerated fear responses triggering various anxiety-, stress-, and trauma-related disorders. However, the underlying mechanisms are not well understood. Here, we investigated the impact of constitutively inactivated 5-HT synthesis on context-dependent fear learning and extinction using tryptophan hydroxylase 2 (Tph2) knockout mice. Fear conditioning and context-dependent fear memory extinction paradigms were combined with c-Fos imaging and electrophysiological recordings in the dorsal hippocampus (dHip). Tph2 mutant mice, completely devoid of 5-HT synthesis in brain, displayed accelerated fear memory formation and increased locomotor responses to foot shock. Furthermore, recall of context-dependent fear memory was increased. The behavioral responses were associated with increased c-Fos expression in the dHip and resistance to foot shock-induced impairment of hippocampal long-term potentiation (LTP). In conclusion, increased context-dependent fear memory resulting from brain 5-HT deficiency involves dysfunction of the hippocampal circuitry controlling contextual representation of fear-related behavioral responses.
Multiple lines of evidence implicate brain serotonin (5-hydroxytryptamine; 5-HT) system dysfunction in the pathophysiology of stressor-related and anxiety disorders. Here we investigate the influence of constitutively deficient 5-HT synthesis on stressor-related anxiety-like behaviors using Tryptophan hydroxylase 2 (Tph2) mutant mice. Functional assessment of c-Fos after associated foot shock, electrophysiological recordings of GABAergic synaptic transmission, differential expression of the Slc6a4 gene in serotonergic neurons were combined with locomotor and anxiety-like measurements in different contextual settings. Our findings indicate that constitutive Tph2 inactivation and consequential lack of 5-HT synthesis in Tph2 null mutant mice (Tph2\(^{-/-}\)) results in increased freezing to associated foot shock and a differential c-Fos activity pattern in the basolateral complex of the amygdala. This is accompanied by altered GABAergic transmission as observed by recordings of inhibitory postsynaptic currents on principal neurons in the basolateral nucleus, which may explain increased fear associated with hyperlocomotion and escape-like responses in aversive inescapable contexts. In contrast, lifelong 5-HT deficiency as observed in Tph2 heterozygous mice (Tph\(^{+/-}\)) is able to be compensated through reduced GABAergic transmission in the basolateral nucleus of the amygdala based on Slc6a4 mRNA upregulation in subdivisions of dorsal raphe neurons. This results in increased activity of the basolateral nucleus of the amygdala due to associated foot shock. In conclusion, our results reflect characteristic syndromal dimensions of panic disorder and agoraphobia. Thus, constitutive lack of 5-HT synthesis influence the risk for anxiety- and stressor-related disorders including panic disorder and comorbid agoraphobia through the absence of GABAergic-dependent compensatory mechanisms in the basolateral nucleus of the amygdala.
Predominant polarity in bipolar disorder and validation of the polarity index in a German sample
(2014)
Background: A large number of patients with bipolar disorder (BD) can be characterized by predominant polarity (PP), which has important implications for relapse prevention. Recently, Popovic et al. (EUR NEUROPSYCHOPHARM 22(5): 339–346, 2012) proposed the Polarity Index (PI) as a helpful tool in the maintenance treatment of BD. As a numeric expression, it reflects the efficacy of drugs used in treatment of BD. In the present retrospective study, we aimed to validate this Index in a large and well characterized German bipolar sample.
Methods: We investigated 336 bipolar patients (BP) according to their PP and calculated the PI for each patient in order to prove if maintenance treatment differs according to their PP. Furthermore, we analysed whether PP is associated with demographic and clinical characteristics of BP.
Results: In our sample, 63.9% of patients fulfilled criteria of PP: 169 patients were classified as depressive predominant polarity (DPP), 46 patients as manic predominant polarity (MPP). The two groups differed significantly in their drug regime: Patients with DPP were more often medicated with lamotrigine and antidepressants, patients with MPP were more often treated with lithium, valproate, carbamazepine and first generation antipsychotics.
However, patients with DPP and MPP did not differ significantly with respect to the PI, although they received evidence-based and guideline-driven treatment.
Conclusion: The reason for this negative finding might well be that for several drugs, which were used frequently, no PI value is available. Nevertheless we suggest PP as an important concept in the planning of BD maintenance treatment.
Fibroblasts isolated from a skin biopsy of a healthy 46-year-old female were infected with Sendai virus containing the Yamanaka factors to produce transgene-free human induced pluripotent stem cells (iPSCs). CRISPR/Cas9 was used to generate isogenic cell lines with a gene dose-dependent deficiency of CDH13, a risk gene associated with neurodevelopmental and psychiatric disorders. Thereby, a heterozygous CDH13 knockout (CDH13\(^{+/-}\)) and a CDH13 null mutant (CDH13\(^{-/-}\)) iPSC line was obtained. All three lines showed expression of pluripotency-associated markers, the ability to differentiate into cells of the three germ layers in vitro, and a normal female karyotype.
The present study investigated changes in cortical oxygenation during mental arithmetic using near-infrared spectroscopy (NIRS). Twenty-nine male volunteers were examined using a 52-channel continuous wave system for analyzing activity in prefrontal areas. With the help of a probabilistic mapping method, three regions of interest (ROIs) on each hemisphere were defined: The inferior frontal gyri (IFG), the middle frontal gyri (MFG), and the superior frontal gyri (SFG). Oxygenation as an indicator of functional brain activation was compared over the three ROI and two levels of arithmetic task difficulty (simple and complex additions). In contrast to most previous studies using fMRI or NIRS, in the present study arithmetic tasks were presented verbally in analogue to many daily life situations. With respect to task difficulty, more complex addition tasks led to higher oxygenation in all defined ROI except in the left IFG compared to simple addition tasks. When compared to the channel positions covering different gyri of the temporal lobe, the observed sensitivity to task complexity was found to be restricted to the specified ROIs. As to the comparison of ROIs, the highest oxygenation was found in the IFG, while MFG and SFG showed significantly less activation compared to IFG. The present cognitive-neuroscience approach demonstrated that NIRS is a suitable and highly feasible research tool for investigating and quantifying neural effects of increasing arithmetic task difficulty.
Nonalcoholic fatty liver disease, induced by a Western diet (WD), evokes central and peripheral inflammation that is accompanied by altered emotionality. These changes can be associated with abnormalities in social behaviour, hippocampus-dependent cognitive functions, and metabolism. Female C57BL/6J mice were fed with a regular chow or with a WD containing 0.2% of cholesterol and 21% of saturated fat for three weeks. WD-treated mice exhibited increased social avoidance, crawl-over and digging behaviours, decreased body-body contacts, and hyperlocomotion. The WD-fed group also displayed deficits in hippocampal-dependent performance such as contextual memory in a fear conditioning and pellet displacement paradigms. A reduction in glucose tolerance and elevated levels of serum cholesterol and leptin were also associated with the WD. The peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1a) mRNA, a marker of mitochondrial activity, was decreased in the prefrontal cortex, hippocampus, hypothalamus, and dorsal raphe, suggesting suppressed brain mitochondrial functions, but not in the liver. This is the first report to show that a WD can profoundly suppress social interactions and induce dominant-like behaviours in naïve adult mice. The spectrum of behaviours that were found to be induced are reminiscent of symptoms associated with autism, and, if paralleled in humans, suggest that a WD might exacerbate autism spectrum disorder.
Reduced function of the serotonin transporter (SERT) is associated with increased susceptibility to anxiety and depression and with type-2 diabetes, which is especially true in older women. Preference for a “Western diet” (WD), enriched with saturated fat, cholesterol, and sugars, may aggravate these conditions. In previous studies, decreased glucose tolerance, central and peripheral inflammation, dyslipidemia, emotional, cognitive, and social abnormalities were reported in WD-fed young female mice. We investigated the metabolic, molecular, and behavioral changes associated with a 3-week-long dietary regime of either the WD or control diet in 12-month-old female mice with three different Sert genotypes: homozygous (Slc6a4) gene knockout (Sert\(^{−/−}\): KO), heterozygous (Sert\(^{+/−}\): HET), or wild-type mice (Sert\(^{+/+}\): WT). In the WT-WD and KO-WD groups, but not in HET-WD-fed mice, most of changes induced by the WD paralleled those found in the younger mice, including brain overexpression of inflammatory marker Toll-like receptor 4 (Tlr4) and impaired hippocampus-dependent performance in the marble test. However, the 12-month-old female mice became obese. Control diet KO mice exhibited impaired hippocampal-dependent behaviors, increased brain expression of the serotonin receptors Htr2c and Htr1b, as well as increased Tlr4 and mitochondrial regulator, peroxisome proliferator-activated receptor gamma-coactivator-1a (Ppargc1a). Paradoxically, these, and other changes, were reversed in KO-WD mutants, suggesting a complex interplay between Sert deficiency and metabolic factors as well as potential compensatory molecular mechanisms that might be disrupted by the WD exposure. Most, but not all, of the changes in gene expression in the brain and liver of KO mice were not exhibited by the HET mice fed with either diet. Some of the WD-induced changes were similar in the KO-WD and HET-WD-fed mice, but the latter displayed a “rescued” phenotype in terms of diet-induced abnormalities in glucose tolerance, neuroinflammation, and hippocampus-dependent performance. Thus, complete versus partial Sert inactivation in aged mice results in distinct metabolic, molecular, and behavioral consequences in response to the WD. Our findings show that Sert\(^{+/−}\) mice are resilient to certain environmental challenges and support the concept of heterosis as evolutionary adaptive mechanism.
Background: There is increasing evidence for the role of prenatal stress in shaping offspring DNA methylation and disease susceptibility. In the current study, we aimed to identify genes and pathways associated with pregnancy anxiety using a genome-wide DNA methylation approach.
Methods: We selected 22 versus 23 newborns from our Prenatal Early Life Stress (PELS) cohort, exposed to the lowest or highest degree of maternal pregnancy anxiety, respectively. Cord blood genome-wide DNA methylation was assayed using the HumanMethylation450 BeadChip (HM450, n = 45) and candidate gene methylation using EpiTYPER (n = 80). Cortisol levels were measured at 2, 4, and 12 months of age to test infant stress system (re)activity.
Results: Data showed ten differentially methylated regions (DMR) when comparing newborns exposed to low versus high pregnancy anxiety scores. We validated a top DMR in the GABA-B receptor subunit 1 gene (GABBR1) revealing the association with pregnancy anxiety particularly in male newborns (most significant CpG Pearson R = 0.517, p = 0.002; average methylation Pearson R = 0.332, p = 0.039). Cord blood GABBR1 methylation was associated with infant cortisol levels in response to a routine vaccination at 4 months old.
Conclusions: In conclusion, our results show that pregnancy anxiety is associated with differential DNA methylation patterns in newborns and that our candidate gene GABBR1 is associated with infant hypothalamic-pituitary-adrenal axis response to a stressor. Our findings reveal a potential role for GABBR1 methylation in association with stress and provide grounds for further research.
Prenatal stress (PS) has been shown to influence the development of the fetal brain and to increase the risk for the development of psychiatric disorders in later life. Furthermore, the variation of human serotonin transporter (5-HTT, SLC6A4) gene was suggested to exert a modulating effect on the association between early life stress and the risk for depression. In the present study, we used a 5-HttxPS paradigm to investigate whether the effects of PS are dependent on the 5-Htt genotype. For this purpose, the effects of PS on cognition, anxiety-and depression-related behavior were examined using a maternal restraint stress paradigm of PS in C57BL6 wild-type (WT) and heterozygous 5-Htt deficient (5-Htt +/-) mice. Additionally, in female offspring, a genome-wide hippocampal gene expression profiling was performed using the Affymetrix GeneChip (R) Mouse Genome 430 2.0 Array. 5-Htt +/- offspring showed enhanced memory performance and signs of reduced anxiety as compared to WT offspring. In contrast, exposure of 5-Htt +/- mice to PS was associated with increased depressive-like behavior, an effect that tended to be more pronounced in female offspring. Further, 5-Htt genotype, PS and their interaction differentially affected the expression of numerous genes and related pathways within the female hippocampus. Specifically, MAPK and neurotrophin signaling were regulated by both the 5-Htt +/- genotype and PS exposure, whereas cytokine and Wnt signaling were affected in a 5-Htt genotypexPS manner, indicating a genexenvironment interaction at the molecular level. In conclusion, our data suggest that although the 5-Htt +/- genotype shows clear adaptive capacity, 5-Htt +/- mice -particularly females-at the same time appear to be more vulnerable to developmental stress exposure when compared to WT offspring. Moreover, hippocampal gene expression profiles suggest that distinct molecular mechanisms mediate the behavioral effects of the 5-Htt genotype, PS exposure, and their interaction.
Cycloid psychoses in the psychosis spectrum: evidence for biochemical differences with schizophrenia
(2016)
Cycloid psychoses (CP) differ from schizophrenia regarding symptom profile, course, and prognosis and over many decades they were thought to be a separate entity within the psychosis spectrum. As to schizophrenia, research into the pathophysiology has focused on dopamine, brain-derived neurotrophic factor, and glutamate signaling in which, concerning the latter, the N-methyl-d-aspartate receptor plays a crucial role. The present study aims to determine whether CP can biochemically be delineated from schizophrenia. Eighty patients referred for psychotic disorders were assessed with the Comprehensive Assessment of Symptoms and History, and (both at inclusion and after 6 weeks of antipsychotic treatment) with the Positive and Negative Syndrome Scale and Clinical Global Impression. From 58 completers, 33 patients were diagnosed with schizophrenia and ten with CP according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and Leonhard criteria, respectively. Fifteen patients were diagnosed with other disorders within the psychosis spectrum. At both time points, blood levels of the dopamine metabolite homovanillic acid, brain-derived neurotrophic factor, and amino acids related to glutamate neurotransmission were measured and compared with a matched control sample. Patients with CP showed a significantly better response to antipsychotic treatment as compared to patients with schizophrenia. In CP, glycine levels were elevated and tryptophan levels were lowered as compared to schizophrenia. Glutamate levels were increased in both patient groups as compared to controls. These results, showing marked differences in both treatment outcome and glutamate-related variable parameters, may point at better neuroplasticity in CP, necessitating demarcation of this subgroup within the psychosis spectrum.
Background and Objectives: Cycloid psychoses are characterized by polymorphic symptomatology with intraphasic bipolarity, a remitting and recurrent course and favourable prognosis. Perris and Brocicington (P&B) described the first set of operational criteria that were partly incorporated in ICD-10. The present study investigates psychopathological profiles according to the P&B criteria and the original descriptions by Leonhard, both against the background of the criteria from the prevailing international classification systems.
Methods: Eighty patients with psychotic disorders were recruited and assessed with various psychometric instruments at baseline and after six weeks of antipsychotic treatment in order to investigate the presence of cycloid psychoses according to Leonhard (LCP) and the effect of treatment with antipsychotics. The overlap between LCP and DSM-IV Brief Psychotic Disorder (BPD), ICD Acute Polymorphic Psychotic Disorder (APP) and P&B criteria was calculated.
Results: Using P&B criteria and a symptom checklist adapted from the original descriptions by Leonhard, 14 and 12 cases of cycloid psychosis were identified respectively reflecting a prevalence of 15-18%. Small though significant concordance rates were found between LCP and both DSM-BPD and ICD-APP. Concordance between LCP and P&B criteria was also significant, but modest.
Conclusions: This study demonstrates that LCP can be identified in a substantial number of patients with psychotic disorders. Cycloid psychoses are not adequately covered in current classification systems and criteria. Since they are demonstrated to have a specific psychopathological profile, relapsing course and favourable prognosis, it is advocated to include these psychoses in daily differential diagnostic procedures.
With the introduction of new genetic techniques such as genome-wide array comparative genomic hybridization, studies on the putative genetic etiology of schizophrenia have focused on the detection of copy number variants (CNVs), ie, microdeletions and/or microduplications, that are estimated to be present in up to 3% of patients with schizophrenia. In this study, out of a sample of 100 patients with psychotic disorders, 80 were investigated by array for the presence of CNVs. The assessment of the severity of psychiatric symptoms was performed using standardized instruments and ICD-10 was applied for diagnostic classification. In three patients, a submicroscopic CNV was demonstrated, one with a loss in 1q21.1 and two with a gain in 1p13.3 and 7q11.2, respectively. The association between these or other CNVs and schizophrenia or schizophrenia-like psychoses and their clinical implications still remain equivocal. While the CNV affected genes may enhance the vulnerability for psychiatric disorders via effects on neuronal architecture, these insights have not resulted in major changes in clinical practice as yet. Therefore, genome-wide array analysis should presently be restricted to those patients in whom psychotic symptoms are paired with other signs, particularly dysmorphisms and intellectual impairment.
Background: While most neuropathologic studies focus on regions involved in behavioral abnormalities in autism, it is also important to identify whether areas that appear functionally normal are devoid of pathologic alterations. In this study we analyzed the posteroinferior occipitotemporal gyrus, an extrastriate area not considered to be affected in autism. This area borders the fusiform gyrus, which is known to exhibit functional and cellular abnormalities in autism.
Findings: No studies have implicated posteroinferior occipitotemporal gyrus dysfunction in autism, leading us to hypothesize that neuropathology would not occur in this area. We indeed observed no significant differences in pyramidal neuron number or size in layers III, V, and VI in seven pairs of autism and controls.
Conclusions: These findings are consistent with the hypothesis that neuropathology is unique to areas involved in stereotypies and social and emotional behaviors, and support the specificity of the localization of pathology in the fusiform gyrus.
Aims
Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF.
Methods and results
Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated glomerular filtration rate (T = −4.7; P < 0.001), alanine aminotransferase (T = −2.1; P = 0.036), and the left atrial end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP but not serum GFAP explained global cerebral atrophy beyond ageing. However, serum GFAP levels were associated with the cognitive domain visual/verbal memory (T = −3.0; P = 0.003) along with focal hippocampal atrophy (T = 2.3; P = 0.025).
Conclusions
Serum GFAP levels are affected by age, smoking, and surrogates of the severity of HF. The association of GFAP with memory dysfunction suggests that astroglial pathologies, which evade detection by conventional MRI, may contribute to memory loss beyond ageing in patients with chronic HF.
Background
Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood.
Methods
Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI).
Results
Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1).
Conclusions
pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers.
Oligodendrocytes provide metabolic and functional support to neuronal cells, rendering them key players in the functioning of the central nervous system. Oligodendrocytes need to be newly formed from a pool of oligodendrocyte precursor cells (OPCs). The differentiation of OPCs into mature and myelinating cells is a multistep process, tightly controlled by spatiotemporal activation and repression of specific growth and transcription factors. While oligodendrocyte turnover is rather slow under physiological conditions, a disruption in this balanced differentiation process, for example in case of a differentiation block, could have devastating consequences during ageing and in pathological conditions, such as multiple sclerosis. Over the recent years, increasing evidence has shown that epigenetic mechanisms, such as DNA methylation, histone modifications, and microRNAs, are major contributors to OPC differentiation. In this review, we discuss how these epigenetic mechanisms orchestrate and influence oligodendrocyte maturation. These insights are a crucial starting point for studies that aim to identify the contribution of epigenetics in demyelinating diseases and may thus provide new therapeutic targets to induce myelin repair in the long run.
Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RIS\(_{am}\)) concentration was found (r\(_s\) = 0.49, p = 0.001) with variation in dose explaining 24% (r\(_s\)\(^2\) = 0.240) of the variability in serum concentrations. While the RIS\(_{am}\) concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RIS\(_{am}\) concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RIS\(_{am}\) was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.
Rats intracerebroventricularily (icv) treated with streptozotocin (STZ), shown to generate an insulin resistant brain state, were used as an animal model for the sporadic form of Alzheimer's disease (sAD). Previously, we showed in an in vivo study that 3 months after STZ icv treatment hippocampal adult neurogenesis (AN) is impaired. In the present study, we examined the effects of STZ on isolated adult hippocampal neural stem cells (NSCs) using an in vitro approach. We revealed that 2.5 mM STZ inhibits the proliferation of NSCs as indicated by reduced number and size of neurospheres as well as by less BrdU-immunoreactive NSCs. Double immunofluorescence stainings of NSCs already being triggered to start with their differentiation showed that STZ primarily impairs the generation of new neurons, but not of astrocytes. For revealing mechanisms possibly involved in mediating STZ effects we analyzed expression levels of insulin/glucose system-related molecules such as the glucose transporter (GLUT) 1 and 3, the insulin receptor (IR) and the insulin-like growth factor (IGF) 1 receptor. Applying quantitative Real time-PCR (qRT-PCR) and immunofluorescence stainings we showed that STZ exerts its strongest effects on GLUT3 expression, as GLUT3 mRNA levels were found to be reduced in NSCs, and less GLUT3-immunoreactive NSCs as well as differentiating cells were detected after STZ treatment. These findings suggest that cultured NSCs are a good model for developing new strategies to treat nerve cell loss in AD and other degenerative disorders.
In a retrospective study of 80 chronic DSM 111-R schizophrenics and 80 controls, the occurrence of obstetric complications (OCs) into the development of chronic schizophrenias was investigated using Leonhard s distinction in systematic schizophrenia (no obvious familial loading) and unsystematic schizophrenia (mainly genetically determined according to Leonhard). The Lewis & Murray and Fuchs scales were used for evaluation. In both scales, unsystematic schizophrenias did not differ from controls, but those with OCs were significantly (p < 0.01) earlier hospitalized (20.5 years) than those without OCs (25.6 years). Systematic schizophrenics had an increased frequency, severity and total score of OCs compared to controls in the Fuchs scale (p < 0.0 I). Likewise, in the Lewis & Murray scale systematic schizophrenia showed an increased presence ofOCs compared to controls (p < 0.05) and to unsystematic schizophrenia (p < 0.1 ). Systematic schizophrenias were significantly allocated to matemal infectious diseases during mid-gestation. Patients with matemal infections showed moreadditional OCs than those without (p < 0.05; Lewis & Murray scale). In systematic schizophrenia, a history of OC was not associated with an early onset of the disease. In the genetic determined schizophrenias prenatal and perinatal disturbanccs Iead to an early onset of the disease, however, in systematic schizophrenias they seem to be of causal importance for the development of the disease.
In 55 chronic schizophrenics, the occurrence of infectious diseases during their mothers' pregnancies was investigated. Different psychiatrie diagnostic systems were compared. Infections were reported by the mothers of familial and sporadic DSM I1I-R schizophrenics in equal proportion. However, applying Leonhard's classification, the frequency of infections was found to be significantly increased in 'systematic' schizophrenia (mainly exogenously induced in the view of Leonhard) compared to 'unsystematic' schizophrenia (mainly genetically determined according to Leonhard's findings). Most of the infections occurred during the second trimester (nine out of 13). Thus, in the 'systematic' forms of schizophrenia (low genetic loading), maternal infections in this crucial period of neurodevelopment would appear to be important causative factors in the cytoarchitectural deviance detected in the central nervous system of schizophrenics.
In 55 chronic DSM I11 -R schi zophre nics the occurrence of obstetr ic complica ti ons (OCs) was investigated us ing the famili al/sporael ic strategy and Leonhard's unsystemati c/systematic distin ction. The overa ll frequency and severity of OCs elid not differ be tween patie nts anel controls. A sub-sample of patients, whose genetic ri sk was supposed to be high in both class ification systems (d iagnos is 01' unsystematic anel fa mili al sc hizophre ni a), had s igni ficantly fewer OCs than controls on the Lewis anel Murray scale (P < 0.05). With reference to previous reports of inc reased morta lity rates in the offspring of schizop hre nics, high genetic risk and addition al perinatal stressors may in crease perin atal mortality. In contrast, pat ie nts whose genetic ri sk was sllpposed to be low in both systems (di agnos is of systematic and sporadic sc hizophrenia) showed a trend to an increased freqllency of OCs in the Fuchs scale. In the context of the recently reported highl y signi ficantly increased rate of matern al infections dllring midgestation in these pati e nts, it was supposed th at perin atal complications may be of so me ae tio logical importance in sc hizophrenics with low genetic ri sk.
We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling existing safety information gaps and inconsistent results. We searched EMBASE, PubMed, and Cochrane Databases of Systematic Reviews and Clinical Trials up to the end of February 2021. Data collection and analysis were conducted using methods described in the Cochrane Handbook for Systematic Reviews of Interventions. All safety outcomes were analyzed based on risk ratios (RR) and their 95% confidence intervals. The meta-analysis pooled 2202 patients from twelve randomized clinical trials, registering non-statistically significant (p > 0.05) differences between Cerebrolysin and placebo throughout main and subgroup analyses. The lowest rate of Serious Adverse Events (SAE), as compared to placebo, was observed for the highest dose of Cerebrolysin (50 mL), highlighting a moderate reduction (RR = 0.6). We observed a tendency of superiority of Cerebrolysin regarding SAE in high dose treatment courses for moderate-severe ischemic stroke, suggesting some effect of the agent against adverse events. This comprehensive safety meta-analysis confirms the safety profile for patients treated with Cerebrolysin after acute ischemic stroke, as compared to placebo.
Low P300 amplitudes and topographical asymmetries have been reponed in schizophrenic patients, but reference-independent amplitude assessment failed to replicate reduced amplitudes. P300 amplitude is conventially assessed at midline electrodes (PZ), anti asymmetric topography as reported in schizophrenics, may conj'ound this measurement. We lnvestigated the possible Interaction between P300 ropography and assessments of amplitudes. ln 41 clinically stable schizophrenics and 31 normal controls, the generalfinding ofreduced amplitudes at the P'l electrode and topographical asymmetrles in the patient group were replicated. ln both groups, a.symmetries of the P300 field (lateralized peaks) reduced the standard amplitude assessment at the midline parletal electrode, but did not Qjfoct the reference-independent, global amplitude assessment. This shows thal asymmetry per se does not imply reduced field strength. in addition, in schizophreraics. but not in controls, there was a significcmt effect oftlae direction of asymmetry on both amplltude measures, amplitudes belng lower with increasing shift ofthe P300 peak to the right side. Considering also the slightly left-lateralized peaks in the normal controls. this suggests rhat only right lateralized P300 peaks upressfunctional deficits in schizophrenics, whereas left lateralized pealcs fall wlthin the physiological variability of the P3OO field. Tht refonnce-independent amplitude assessment is proposed for unambiguous amplitude assessment in order to better define the clinical, psychological and physiopathological mtaning of the P3OO alterations in schizophrenics.
Evidence of hemispheric asymmetries in schizophrenia has been reported from different research areas. Asymmetries in evoked potential P300 topography are still controversial because of inconsistent findings. In the present study. previous results of abnormal lateralization of P300 were replicated in stabilized residual Schizophrenie patients. Auditory P300 was recorded during an odd ball task in which subjeets detected rare target stimuli. Schizophrenie patients had the P300 peak shifted to the right hemisphere and differed signifieantly from age- and sex-matched normal control subjects who had left-lateralized P300 peaks. A comparison of different methods of assessment and analysis of the topographical features of the P300 electric fields showed that the extraction of reference-independent descriptors of P300 topography is a reliable and sensitive method for statistical handling of the maps. The results suggest left hemispheric dysfunction during cognitive tasks in a subgroup of Schizophrenie patients. Inconsistencies between previous sturlies are likely to be due to heterogeneous patient groups, which may have included patients in an acute Schizophrenie episode or patients in clinical remission. lnvestigation of the clinical meaning of P300 alterations requires careful psychopathological definition of the patient groups.
While deficient brain plasticity is a well-established pathophysiologic feature of depression, little is known about disorder-associated enhanced cognitive processing. Here, we studied a novel mouse paradigm that potentially models augmented learning of adverse memories during development of a depressive-like state. We used a modification of the classic two-day protocol of a mouse Porsolt test with an additional session occurring on Day 5 following the initial exposure. Unexpectedly, floating behaviour and brain glycogen synthase kinase-3 beta (GSK-3beta) mRNA levels, a factor of synaptic plasticity as well as a marker of distress and depression, were increased during the additional swimming session that was prevented by imipramine. Observed increases of GSK-3beta mRNA in prefrontal cortex during delayed testing session correlated with individual parameters of behavioural despair that was not found in the classic Porsolt test. Repeated swim exposure was accompanied by a lower pGSK-3beta/GSK-3beta ratio. A replacement of the second or the final swim sessions with exposure to the context of testing resulted in increased GSK-3beta mRNA level similar to the effects of swimming, while exclusion of the second testing prevented these changes. Together, our findings implicate the activation of brain GSK-3beta expression in enhanced contextual conditioning of adverse memories, which is associated with an individual susceptibility to a depressive syndrome.
Serotonin receptor 1A gene (HTR1A) knockout mice show pronounced defensive behaviour and increased fear conditioning to ambiguous conditioned stimuli. Such behaviour is a hallmark of pathological human anxiety, as observed in panic disorder with agoraphobia (PD/AG). Thus, variations in HTR1A might contribute to neurophysiological differences within subgroups of PD/AG patients. Here, we tested this hypothesis by combining genetic with behavioural techniques and neuroimaging. In a clinical multicentre trial, patients with PD/AG received 12 sessions of manualized cognitive-behavioural therapy (CBT) and were genotyped for HTR1A rs6295. In four subsamples of this multicentre trial, exposure behaviour (n = 185), defensive reactivity measured using a behavioural avoidance test (BAT; before CBT: n = 245; after CBT: n = 171) and functional magnetic resonance imaging (fMRI) data during fear conditioning were acquired before and after CBT (n = 39). HTR1A risk genotype (GG) carriers more often escaped during the BAT before treatment. Exploratory fMRI results suggest increased activation of the amygdala in response to threat as well as safety cues before and after treatment in GG carriers. Furthermore, GG carriers demonstrated reduced effects of CBT on differential conditioning in regions including the bilateral insulae and the anterior cingulate cortex. Finally, risk genotype carriers demonstrated reduced self-initiated exposure behaviour to aversive situations. This study demonstrates the effect of HTR1A variation on defensive behaviour, amygdala activity, CBT-induced neural plasticity and normalization of defence behaviour in PD/AG. Our results, therefore, translate evidence from animal studies to humans and suggest a central role for HTR1A in differentiating subgroups of patients with anxiety disorders.